NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RNA

Avidity Biosciences Inc

Jul 03 • 04:00PM ET

29.17

Dollar change -0.19
Percentage change -0.65	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

| Held by: VTI IWM VXF XBI VB VBR IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.01	Insider Own	8.87%	Shs Outstand	120.51M	Perf Week	-2.21%
Market Cap	3.52B	Forward P/E	-	EPS next Y	-4.39	Insider Trans	-1.62%	Shs Float	109.84M	Perf Month	-15.23%
Enterprise Value	2.14B	PEG	-	EPS next Q	-0.95	Inst Own	107.70%	Short Float	14.88%	Perf Quarter	-2.02%
Income	-369.22M	P/S	393.74	EPS this Y	-36.11%	Inst Trans	7.65%	Short Ratio	11.27	Perf Half Y	-0.03%
Sales	8.93M	P/B	2.65	EPS next Y	-11.63%	ROA	-30.63%	Short Interest	16.34M	Perf YTD	0.31%
Book/sh	11.03	P/C	2.55	EPS next 5Y	-4.03%	ROE	-34.19%	52W High	56.00 -47.91%	Perf Year	-29.34%
Cash/sh	11.45	P/FCF	-	EPS past 3/5Y	-0.47% -34.37%	ROIC	-27.74%	52W Low	21.51 35.61%	Perf 3Y	106.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.33% 36.27%	Gross Margin	67.29%	Volatility	5.01% 5.57%	Perf 5Y	9.58%
Dividend TTM	-	EV/Sales	239.89	EPS Y/Y TTM	-1.89%	Oper. Margin	-4853.44%	ATR (14)	1.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.91	Sales Y/Y TTM	-17.87%	Profit Margin	-4136.00%	RSI (14)	43.92	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	16.91	EPS Q/Q	-13.46%	SMA20	-5.07%	Beta	0.93	Target Price	67.24
Payout	-	Debt/Eq	0.00	Sales Q/Q	-55.60%	SMA50	-5.03%	Rel Volume	0.38	Prev Close	29.36
Employees	391	LT Debt/Eq	0.00	Earnings	May 08 AMC	SMA200	-16.19%	Avg Volume	1.45M	Price	29.17
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.80% -32.41%	Trades		Volume	553,948	Change	-0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37
Jul-07-20	Initiated	Wells Fargo	Overweight	$60

Show Previous Ratings

Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga) -9.88%
07:01AM	Loading…
07:01AM	Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants (PR Newswire)
07:00AM	Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD (PR Newswire)
May-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.63%
04:05PM	Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
May-06-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire) -18.65%
Apr-24-25 05:15PM	Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +6.98%
04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Loading…
Apr-08-25 09:00AM	Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire) -5.49%
Apr-05-25 05:22PM	Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks) -5.61%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.42%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Mar-31-25 09:00AM	Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire) -6.58%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.98%
Mar-17-25 07:00AM	Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44 Trial (PR Newswire) +8.74%
Mar-12-25 04:05PM	Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire) +10.24%
Feb-28-25 09:00AM	Avidity Biosciences Honors Rare Disease Day and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases (PR Newswire) +5.36%
Feb-27-25 05:40PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Feb-25-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
04:05PM	Loading…
Feb-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-20-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-17-25 11:06AM	Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-08-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire)
Jan-01-25 01:12PM	Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-20-24 05:00PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-26-24 10:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily) +12.35%
Nov-12-24 07:00AM	Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations (PR Newswire)
Nov-07-24 06:10PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
Nov-06-24 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Oct-31-24 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 (PR Newswire)
Oct-30-24 08:00AM	Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Oct-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.41%
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-04-24 07:00PM	Why Avidity Biosciences Zoomed to a 12% Gain This Week (Motley Fool) -7.08%
10:53AM	FDA lifts clinical hold on Aviditys lead antibody conjugate therapy trial (Pharmaceutical Technology)
Oct-03-24 07:00AM	Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) (PR Newswire)
Sep-29-24 06:27AM	Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 07:34PM	Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey) -8.23%
Sep-25-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Sep-23-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 09:00AM	Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month (PR Newswire)
Aug-28-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-20-24 07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 09:00AM	Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-14-24 08:30PM	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +6.16%
Aug-13-24 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Aug-09-24 08:53PM	RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace) +12.13% -5.26%
05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:17PM	How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics (Investor's Business Daily)
04:05PM	Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
07:00AM	Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial (PR Newswire)
Aug-05-24 09:15AM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer (PR Newswire)
Jul-24-24 06:41AM	3 Stocks Doing Even Better Than Superstar Super Micro (SMCI) (InvestorPlace)
Jul-23-24 07:00AM	3 Russell 2000 Growth Stocks That Could Be Worth the Risk (Motley Fool)
Jul-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-03-24 06:53AM	Aviditys FSHD drug del-brax shows promise in Phase I/II trial (Clinical Trials Arena)
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-14-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Jun-13-24 08:00PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire)
10:39AM	Avidity (RNA) Up 33% on Rare Muscle Disease Study Results (Zacks)
Jun-12-24 04:04PM	The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record (Investor's Business Daily) +32.64%
04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
07:45AM	Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss (BioPharma Dive)
07:00AM	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%
May-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-17-24 03:24AM	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:00AM	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors (PR Newswire)
May-09-24 11:55PM	RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
May-08-24 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
12:27PM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 (MT Newswires)
06:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Apr-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.29%
Apr-04-24 01:30AM	Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares (GuruFocus.com) -11.07%
Mar-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Jun 12 06:18 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Sale	32.88	20,000	657,694	80,195	Jun 12 06:18 PM
WILLIAM MICHAEL FLANAGAN	Officer	Jun 11 '25	Proposed Sale	33.62	20,000	672,400		Jun 11 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Option Exercise	16.65	5,875	97,819	56,429	Jun 04 04:48 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Sale	32.48	5,875	190,833	50,554	Jun 04 04:48 PM
KATHLEEN GALLAGHER	Officer	Jun 02 '25	Proposed Sale	30.98	5,875	182,008		Jun 02 04:37 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Option Exercise	16.65	5,875	97,819	56,429	May 02 07:55 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Sale	32.40	5,875	190,324	50,554	May 02 07:55 PM
KATHLEEN GALLAGHER	Officer	May 01 '25	Proposed Sale	32.65	5,875	191,819		May 01 04:57 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Option Exercise	14.81	5,875	87,004	56,100	Apr 03 04:56 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Sale	27.83	5,875	163,486	50,554	Apr 03 04:56 PM
Hughes Steven George	Chief Medical Officer	Mar 20 '25	Sale	31.06	9,578	297,491	72,850	Mar 21 06:44 PM
Boyce Sarah	President and CEO	Mar 20 '25	Sale	31.06	31,540	979,563	305,871	Mar 21 06:42 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 20 '25	Sale	31.06	11,780	365,868	80,195	Mar 21 06:40 PM
MacLean Michael F	Chief Financial Officer	Mar 20 '25	Sale	31.06	7,935	246,425	96,720	Mar 21 06:38 PM
McCarthy Teresa	Chief Human Resources Officer	Mar 20 '25	Sale	31.06	7,778	241,583	97,130	Mar 21 06:36 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Option Exercise	14.22	20,000	284,400	111,975	Mar 12 04:23 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 11 '25	Sale	30.13	20,000	602,614	91,975	Mar 12 04:23 PM
WILLIAM MICHAEL FLANAGAN	Officer	Mar 11 '25	Proposed Sale	30.04	20,000	600,800		Mar 11 04:35 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Option Exercise	14.70	5,875	86,362	56,429	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Mar 03 '25	Sale	29.41	5,875	172,807	50,554	Mar 04 06:17 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Option Exercise	16.65	5,875	97,819	56,429	Feb 05 05:01 PM
Gallagher Kathleen P.	Chief Program Officer	Feb 03 '25	Sale	32.16	5,875	188,918	50,554	Feb 05 05:01 PM
KATHLEEN GALLAGHER	Officer	Feb 03 '25	Proposed Sale	32.93	17,625	580,391		Feb 03 04:34 PM
LEVIN ARTHUR A	Director	Jan 21 '25	Sale	28.60	1,872	53,537	12,958	Jan 23 08:17 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '25	Sale	28.59	3,287	93,985	104,655	Jan 23 08:15 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '25	Sale	28.59	2,959	84,612	104,908	Jan 23 08:14 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '25	Sale	28.60	5,672	162,192	91,975	Jan 23 08:12 PM
Boyce Sarah	President and CEO	Jan 21 '25	Sale	28.59	10,397	297,291	337,411	Jan 23 08:10 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 22 '25	Sale	30.16	5,629	169,776	50,554	Jan 23 08:08 PM
Gallagher Kathleen P.	Chief Program Officer	Jan 21 '25	Sale	28.59	3,782	108,136	56,183	Jan 23 08:08 PM
Hughes Steven George	Chief Medical Officer	Jan 21 '25	Sale	28.59	3,947	112,856	82,428	Jan 23 08:06 PM
KATHLEEN GALLAGHER	Officer	Jan 22 '25	Proposed Sale	30.84	6,924	213,536		Jan 22 04:25 PM
Flanagan W. Michael	CSTO	Dec 18 '24	Sale	32.66	12,742	416,154	72,647	Dec 19 06:17 PM
MacLean Michael F	Chief Financial Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,942	Dec 19 06:16 PM
Boyce Sarah	President and CEO	Dec 18 '24	Sale	32.66	31,855	1,040,384	265,308	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 18 '24	Sale	32.66	11,151	364,192	82,867	Dec 19 06:15 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Dec 18 04:46 PM
McCarthy Teresa	Chief Human Resources Officer	Dec 16 '24	Sale	33.26	25,000	831,605	94,018	Dec 18 04:46 PM
TERESA MCCARTHY	Officer	Dec 16 '24	Proposed Sale	32.49	25,000	812,250		Dec 16 04:29 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Option Exercise	22.47	24,000	539,280	109,389	Dec 13 06:08 PM
Flanagan W. Michael	CSTO	Dec 11 '24	Sale	35.77	24,000	858,401	85,389	Dec 13 06:08 PM
W. MICHAEL FLANAGAN	Officer	Dec 11 '24	Proposed Sale	36.10	24,000	866,400		Dec 11 04:59 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Option Exercise	14.22	25,000	355,500	119,018	Nov 20 06:10 PM
McCarthy Teresa	Chief Human Resources Officer	Nov 18 '24	Sale	41.14	25,000	1,028,520	94,018	Nov 20 06:10 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Option Exercise	1.24	3,323	4,121	18,153	Nov 20 06:06 PM
LEVIN ARTHUR A	Director	Nov 19 '24	Sale	42.12	3,323	139,973	14,830	Nov 20 06:06 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Option Exercise	8.43	79,057	666,064	159,275	Nov 08 04:50 PM
MacLean Michael F	Chief Financial Officer	Nov 06 '24	Sale	45.56	106,319	4,843,979	94,093	Nov 08 04:50 PM
MICHAEL MACLEAN	Officer	Nov 06 '24	Proposed Sale	45.09	106,319	4,793,924		Nov 06 04:56 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Option Exercise	1.24	5,000	6,200	19,830	Oct 23 04:19 PM
LEVIN ARTHUR A	Director	Oct 21 '24	Sale	46.63	5,000	233,168	14,830	Oct 23 04:19 PM
ARTHUR A LEVIN	Director	Oct 21 '24	Proposed Sale	50.45	8,323	419,895		Oct 21 04:21 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Option Exercise	14.22	25,000	355,500	119,018	Oct 17 04:20 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 16 '24	Sale	48.52	25,000	1,213,010	94,018	Oct 17 04:20 PM
LEVIN ARTHUR A	Officer	Oct 16 '24	Proposed Sale	46.60	22,500	1,048,500		Oct 16 01:48 PM
Thompson Tamar	Director	Oct 07 '24	Option Exercise	27.63	30,000	828,900	30,000	Oct 09 05:23 PM
Thompson Tamar	Director	Oct 07 '24	Sale	44.98	30,000	1,349,259	0	Oct 09 05:23 PM
Thompson Tamar	Officer	Oct 07 '24	Proposed Sale	47.30	30,000	1,419,000		Oct 07 04:39 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Option Exercise	26.75	62,500	1,671,875	147,889	Oct 03 04:09 PM
Flanagan W. Michael	CSTO	Oct 01 '24	Sale	47.62	62,500	2,976,112	85,389	Oct 03 04:09 PM
WILLIAM MICHAEL FLANAGAN	Officer	Oct 01 '24	Proposed Sale	45.93	38,018	1,746,167		Oct 01 04:36 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 23 '24	Sale	44.00	13,153	578,737	69,018	Sep 23 09:06 PM
Flanagan W. Michael	CSTO	Sep 23 '24	Sale	43.95	25,000	1,098,733	72,718	Sep 23 09:03 PM
Boyce Sarah	President and CEO	Sep 23 '24	Sale	44.00	32,880	1,446,723	234,663	Sep 23 09:01 PM
MacLean Michael F	Chief Financial Officer	Sep 23 '24	Sale	44.00	11,510	506,440	96,355	Sep 23 08:59 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 23 '24	Proposed Sale	44.48	36,329	1,615,914		Sep 23 04:27 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Sep 20 05:19 PM
LEVIN ARTHUR A	Director	Sep 19 '24	Sale	45.73	5,000	228,658	14,830	Sep 20 05:19 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Option Exercise	25.24	96,500	2,435,855	138,265	Sep 13 04:25 PM
Flanagan W. Michael	CSTO	Sep 11 '24	Sale	40.40	111,394	4,500,244	60,871	Sep 13 04:25 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Option Exercise	14.22	25,000	355,500	82,171	Sep 13 04:17 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 11 '24	Sale	40.40	25,000	1,010,042	57,171	Sep 13 04:17 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '24	Proposed Sale	40.79	111,394	4,543,761		Sep 11 04:18 PM
TERESA MCCARTHY	Officer	Sep 11 '24	Proposed Sale	40.79	75,000	3,059,250		Sep 11 04:18 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Aug 21 04:30 PM
LEVIN ARTHUR A	Director	Aug 19 '24	Sale	45.19	5,000	225,946	14,830	Aug 21 04:30 PM
Boyce Sarah	President and CEO	Aug 06 '24	Option Exercise	1.24	28,000	34,720	233,043	Aug 07 05:46 PM
Boyce Sarah	President and CEO	Aug 06 '24	Sale	43.35	28,000	1,213,822	205,043	Aug 07 05:46 PM
LEVIN ARTHUR A	Director	Jul 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Jul 23 04:22 PM
LEVIN ARTHUR A	Director	Jul 19 '24	Sale	45.01	5,000	225,069	14,830	Jul 23 04:22 PM
Boyce Sarah	President and CEO	Jul 09 '24	Option Exercise	1.24	28,000	34,720	233,043	Jul 11 04:07 PM
Boyce Sarah	President and CEO	Jul 09 '24	Sale	39.93	28,000	1,118,082	205,043	Jul 11 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNA

Avidity Biosciences Inc

Upgrade your FINVIZ experience